DNA sequencing pioneer named as BBSRC Innovator of the Year
Prof Shankar Balasubramanian is recognised for the invention of Solexa genome sequencing
Balasubramanian, from the University of Cambridge, is the inventor of Solexa sequencing, an ultrafast method for sequencing DNA. He founded Solexa with colleagues in 1998. Following several rounds of fund raising and the launch of its core product, The Genome Analyser, the company was sold to Illumina for US$600m in 2007. The Solexa product currently has a 50% market share in next generation sequencing and can sequence a human genome for under US$10,000.
Balasubramanian also won the Commercial Innovator of the Year category.
Dr Michael McArthur from the John Innes Centre was awarded £5,000 as the winner of Most Promising Innovator of the Year for his work on using novel antibacterials to combat drug resistant bacterial infections.
Science and Innovation Minister Lord Drayson said: ‘Turning research into innovation is crucial for our future prosperity. Finding practical applications for scientific discoveries is part of the joy of science. Today's winners make science exciting and relevant, with the potential to generate great benefits for our economy and society.’
Balasubramanian accepted the Innovator of the Year Award on behalf of the many people who have made important contributions to the Solexa project, particularly his departmental colleague, Prof David Klenerman, with whom he co-founded Solexa in 1998.
‘None of this would have happened without the support of BBSRC. Their backing was essential for the blue skies research that gave rise to our original inventions. The continued funding of fundamental science by BBSRC will be an essential part of future enterprises and ultimately, wealth creation,’ he said.
The Innovator of the Year Award, now in its second year, recognises and rewards scientists who are ensuring that the UK's bioscience research is translated into outcomes that positively affect quality of life for everyone.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development
VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development
The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies
Research & Development
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
The pair will advance their strategic partnership to the next phase of clinical trials for Brainomix's e-Lung after strong initial results demonstrated its potential to enable earlier diagnosis of progressive pulmonary fibrosis